Your browser doesn't support javascript.
loading
Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis.
Granberg, Tobias; Moridi, Thomas; Brand, Judith S; Neumann, Susanne; Hlavica, Martin; Piehl, Fredrik; Ineichen, Benjamin V.
Affiliation
  • Granberg T; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Moridi T; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
  • Brand JS; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Neumann S; Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, 70185, Örebro, Sweden.
  • Hlavica M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Piehl F; Department of Neurosurgery, Inselspital, University of Bern, Bern, Switzerland.
  • Ineichen BV; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
J Neurol ; 267(11): 3199-3212, 2020 Nov.
Article in En | MEDLINE | ID: mdl-32535680
ABSTRACT

BACKGROUND:

Perivascular spaces can become detectable on magnetic resonance imaging (MRI) upon enlargement, referred to as enlarged perivascular spaces (EPVS) or Virchow-Robin spaces. EPVS have been linked to small vessel disease. Some studies have also indicated an association of EPVS to neuroinflammation and/or neurodegeneration. However, there is conflicting evidence with regards to their potential as a clinically relevant imaging biomarker in multiple sclerosis (MS).

METHODS:

To perform a systematic review and meta-analysis of EPVS as visualized by MRI in MS. Nine out of 299 original studies addressing EPVS in humans using MRI were eligible for the systematic review and meta-analysis including a total of 457 MS patients and 352 control subjects.

RESULTS:

In MS, EPVS have been associated with cognitive decline, contrast-enhancing MRI lesions, and brain atrophy. Yet, these associations were not consistent between studies. The meta-analysis revealed that MS patients have greater EPVS prevalence (odds ratio = 4.61, 95% CI = [1.84; 11.60], p = 0.001) as well as higher EPVS counts (standardized mean difference [SMD] = 0.46, 95% CI = [0.26; 0.67], p < 0.001) and larger volumes (SMD = 0.88, 95% CI = [0.19; 1.56], p = 0.01) compared to controls.

CONCLUSIONS:

Available literature suggests a higher EPVS burden in MS patients compared to controls. The association of EPVS to neuroinflammatory or -degenerative pathology in MS remains inconsistent. Thus, there is currently insufficient evidence supporting EPVS as diagnostic and/or prognostic marker in MS. In order to benefit future comparisons of studies, we propose recommendations on EPVS assessment standardization in MS. PROSPERO No CRD42019133946.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cognitive Dysfunction / Glymphatic System / Multiple Sclerosis Type of study: Guideline / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: J Neurol Year: 2020 Document type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cognitive Dysfunction / Glymphatic System / Multiple Sclerosis Type of study: Guideline / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: J Neurol Year: 2020 Document type: Article Affiliation country: Sweden